On January 18, the U.S. Food and Drug Administration (FDA) approved etravirine (TMC125 or Intelence™) tablets for use in combination with other antiretrovirals for the treatment of adults who have experienced treatment failure with other antiretrovirals. Granted a "priority review," etravirine is the newest non-nucleoside reverse transcriptase inhibitor (NNRTI) to receive FDA approval. The most common side effects that were reported during clinical trials were skin rashes and nausea.
Indicates this file is in Adobe PDF format and requires the Adobe Acrobat Reader program.
Spring 2008 Newsletter / Volume 9, Issue 3
Indicates this file is in Adobe PDF format and requires the Adobe Acrobat Reader program.